Related Experiment Videos
Intrathecal interferon in subacute sclerosing panencephalitis
Abstract:
Five patients with clinically advanced subacute sclerosing panencephalitis (SSPE) were given human leukocyte interferon (IFN) by the lumbar route, 1 million IU every other day for a total of 30 days. Intrathecal IFN produced a meningeal inflammatory reaction in all patients and was associated with transient hemiparesis in 1. It persisted in the cerebrospinal fluid at measurable levels for 48 hours after a single injection. Although improvement was temporally related to intrathecal IFN in 1 patient, it is not clear whether this was induced by IFN or a spontaneous remission. A randomized controlled trial would be necessary to evaluate IFN critically as a therapy for SSPE.
Insights
Human leukocyte interferon (IFN) administered intrathecally for subacute sclerosing panencephalitis (SSPE) caused inflammation and temporary weakness in some patients. Further trials are needed to confirm IFN
Area of Science:
- Neurology
- Immunology
- Virology
Background:
- Subacute sclerosing panencephalitis (SSPE) is a rare, progressive neurological disorder.
- Current treatments for advanced SSPE are limited.
Purpose of the Study:
- To evaluate the safety and potential efficacy of intrathecal human leukocyte interferon (IFN) in patients with advanced SSPE.
Main Methods:
- Five patients with advanced SSPE received 1 million IU of intrathecal IFN every other day for 30 days.
- Cerebrospinal fluid (CSF) levels of IFN were monitored.
Main Results:
- Intrathecal IFN induced a meningeal inflammatory reaction in all patients.
- Transient hemiparesis occurred in one patient.
- IFN was detectable in CSF for 48 hours post-injection.
Conclusions:
- Intrathecal IFN administration in advanced SSPE patients led to inflammatory reactions and transient neurological deficits.
- While one patient showed temporary improvement, it is unclear if this was due to IFN or spontaneous remission.
- A randomized controlled trial is essential to critically assess the therapeutic value of IFN for SSPE.